TALACEN
LOE ApproachingNDAORALTABLET
Approved
Sep 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TALACEN is an oral small-molecule tablet approved by Sanofi in 1982. The mechanism of action and indications are not publicly specified in available data. This product represents a legacy small-molecule therapeutic with four decades of clinical use.
LOE Approaching
As LOE approaches, brand team focus will shift from growth optimization to lifecycle extension and managed decline; headcount reductions or role consolidation are typical.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect the product's mature, declining lifecycle stage. Roles on TALACEN typically involve managing market share erosion and optimizing existing patient bases rather than expansion. Career progression on this asset is limited; professionals should expect smaller teams and potential transitions to newer products.
Brand ManagerField Sales Representative
Worked on TALACEN at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.